Gene:
RELB
v-rel avian reticuloendotheliosis viral oncogene homolog B

PharmGKB contains no dosing guidelines for this . To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.

PharmGKB has no annotated drug labels with pharmacogenomic information for this . If you know of a drug label with PGx, send us a message.

PharmGKB contains no Clinical Variants that meet the highest level of criteria.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

Overview

Alternate Names:  v-rel reticuloendotheliosis viral oncogene homolog B
Alternate Symbols:  REL-B
PharmGKB Accession Id: PA34322

Details

Cytogenetic Location: chr19 : q13.32 - q13.32
GP mRNA Boundary: chr19 : 45504707 - 45541456
GP Gene Boundary: chr19 : 45494707 - 45544456
Strand: plus

Visualization

UCSC has a Genome Browser that you can use to view PharmGKB annotations for this gene in context with many other sources of information.

View on UCSC Browser
The mRNA boundaries are calculated using the gene's default feature set from NCBI, mapped onto the UCSC Golden Path. PharmGKB sets gene boundaries by expanding the mRNA boundaries by no less than 10,000 bases upstream (5') and 3,000 bases downstream (3') to allow for potential regulatory regions.

PharmGKB Curated Pathways

Pathways created internally by PharmGKB based primarily on literature evidence.

  1. Tacrolimus/Cyclosporine Pathway, Pharmacodynamics
    Stylized cell depicting the mechanism of action of tacrolimus and cyclosporine, as well as the candidate genes believed to interact with the two drugs.

External Pathways

Links to non-PharmGKB pathways.

PharmGKB contains no links to external pathways for this gene. To report a pathway, click here.

Curated Information ?

No related diseases are available

LinkOuts

NCBI Gene:
5971
OMIM:
604758
UCSC Genome Browser:
NM_006509
RefSeq RNA:
NM_006509
RefSeq Protein:
NP_006500
RefSeq DNA:
NT_011109
UniProtKB:
RELB_HUMAN (Q01201)
Ensembl:
ENSG00000104856
GenAtlas:
RELB
GeneCard:
RELB
MutDB:
RELB
ALFRED:
LO186819H
HuGE:
RELB
Comparative Toxicogenomics Database:
5971
ModBase:
Q01201
HumanCyc Gene:
HS02635
HGNC:
9956

Common Searches